Shire expands rare disease reach

Share this article:

Shire, which is soon to be AbbVie, has finalized a deal with US biotech ArmaGen. The $225-million deal gives Shire worldwide commercialization rights to the experimental enzyme replacement therapy AGT-182, which could be used to treat what the firms describe in a statement as “the central nervous system (CNS) and somatic manifestations in patients with Hunter syndrome.”

Hunter syndrome is a rare disease in which the body can't get rid of cellular waste. Around 1,200 patients have been diagnosed with the genetic disorder.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.